<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947619</url>
  </required_header>
  <id_info>
    <org_study_id>06250</org_study_id>
    <nct_id>NCT03947619</nct_id>
  </id_info>
  <brief_title>Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial</brief_title>
  <acronym>DTU-STEMI</acronym>
  <official_title>Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abiomed Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate whether using the the IMPELLA® CP System
      temporary circulatory assist device for 30 minutes prior to a catheterization procedure has
      the potential to reduce the damage to the heart caused by a heart attack, compared to the
      current standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the safety and effectiveness of primary Left Ventricular unloading and a
      thirty-minutes delay to reperfusion vs. current standard of care in reducing infarct size and
      heart failure-related clinical events in patients presenting with anterior ST-Elevation
      Myocardial Infarction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>A prospective, multicenter, randomized, controlled open-label two-arm trial with an adaptive design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinding of the operator and patient is not possible given the nature of the treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct Size</measure>
    <time_frame>3-5 days post-procedure</time_frame>
    <description>Infarct size normalized to the left ventricular mass, evaluated using Cardiac Magnetic Resonance (CMR) imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct Size, as a percent of Left Ventricular Mass</measure>
    <time_frame>3-5 days</time_frame>
    <description>Efficacy- Composite clinical secondary endpoint, Compared between groups in a hierarchical order using the Finkelstein-Schoenfeld statistic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impella CP® related Major Bleeding and Major Vascular complications</measure>
    <time_frame>30 Days</time_frame>
    <description>Efficacy (Cardiogenic Shock)- Composite clinical secondary endpoint. Compared between groups in a hierarchical order using the Finkelstein-Schoenfeld statistic. Secondary Safety (Major Bleeding and Vascular Complications); with pre-specified performance goals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiogenic Shock, CV mortality, Heart Failure, LVAD or Heart Transplant and ICD or CRT Placement</measure>
    <time_frame>12 Months</time_frame>
    <description>Efficacy- Composite clinical secondary endpoint. Compared between groups in a hierarchical order using the Finkelstein-Schoenfeld statistic.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">668</enrollment>
  <condition>ST Elevation (STEMI) Myocardial Infarction of Anterior Wall</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the experimental arm will have their heart unloaded for 30 minutes on the Impella CP® device prior to PCI.
Each site is required to have one &quot;roll-in&quot; per arm to test the study protocol before beginning enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Primary PCI. Each site is required to have one &quot;roll-in&quot; per arm to test the study protocol before beginning enrollment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella CP® placement prior to reperfusion with Primary PCI</intervention_name>
    <description>Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years

          2. First myocardial infarction

          3. Acute anterior STEMI with ≥2 mm in 2 or more contiguous anterior leads or ≥ 4 mm total
             ST segment deviation sum in the anterior leads V1-V4

          4. Patient presents to the hospital between 1 - 5 hours of chest pain onset

          5. Patient indicated for Primary PCI

          6. Patient or the patient's Legally Authorized Representative (where applicable) has
             signed Informed Consent

        Exclusion Criteria:

          1. Patient transferred from an outside hospital where invasive coronary procedure was
             attempted (including diagnostic catheterization)

          2. Unwitnessed cardiac arrest OR ≥30 minutes of CPR prior to enrollment OR any impairment
             in mental status, cognition, or any global or focal neurological deficit

          3. Administration of fibrinolytic therapy within 24 hours prior to enrollment

          4. Cardiogenic shock defined as: systemic hypotension (systolic BP &lt;90 mmHg or the need
             for inotropes/pressors to maintain a systolic BP &gt;90mmHg) plus one of the following:
             any requirement for pressors/inotropes prior to arrival at the catheterization
             laboratory, clinical evidence of end organ hypoperfusion or use of IABP or any other
             circulatory support device

          5. Inferior STEMI or suspected right ventricular failure

          6. Any contraindication or inability to place the Impella, including peripheral vascular
             disease, tortuous vascular anatomy, femoral bruits or absent pedal pulses

          7. Severe aortic stenosis

          8. Acute cardiac mechanical complication: LV free wall rupture OR Interventricular septum
             rupture OR Acute mitral regurgitation

          9. Suspected or known pregnancy

         10. Suspected systemic active infection

         11. History or known hepatic insufficiency prior to catheterization

         12. On renal replacement therapy

         13. COPD with home oxygen therapy or on chronic steroid therapy

         14. Known or evidence of prior myocardial infarction, including pathologic Q waves in
             non-anterior leads

         15. Prior CABG or LAD PCI

         16. History of heart failure

         17. Prior aortic valve surgery or TAVR

         18. Left bundle branch block (new or old)

         19. History of stroke/TIA within the prior 3 months, any history of Intracranial
             Hemorrhage or any permanent neurological deficit

         20. History of bleeding diathesis or known coagulopathy (including heparin-induced
             thrombocytopenia), any recent GU or GI bleed, or will refuse blood transfusions

         21. Patient on systemic anticoagulation pre-procedure (including factor Xa inhibitors,
             thrombin inhibitors, warfarin)

             Known contraindication to:

         22. Undergoing MRI or use of gadolinium, e.g. CrCl&lt;30 ml/min, non-compatible implant,
             claustrophobia

         23. Heparin, pork, pork products or contrast media

         24. Receiving a drug-eluting stent

         25. Participation in the active treatment or follow-up phase of another clinical study of
             an investigational drug or device which has not reached its primary end point.

         26. Any organ condition, concomitant disease (e.g., psychiatric illness, severe
             alcoholism, or drug abuse, severe cancer, hepatic or kidney disease), with life
             expectancy of ≤2 years or other abnormality that itself, or the treatment of which,
             could interfere with the conduct of the study or that, in the opinion of the
             Investigator and/or Sponsor's medical monitor, would pose an unacceptable risk to the
             patient in the study.

         27. Subject has other medical, social, or psychological problems that, in the opinion of
             the Investigator, compromises the subject's ability to give written informed consent
             and/or to comply with study procedures, including follow-up CMRs.

         28. Subject belongs to a vulnerable population [Vulnerable patient populations are defined
             as Individuals with mental disability, persons in nursing homes, children,
             impoverished persons, homeless persons, nomads, refugees, and those permanently
             incapable of giving informed consent. Vulnerable populations also may include members
             of a group with a hierarchical structure such as university students, subordinate
             hospital and laboratory personnel, employees of the Sponsor, members of the armed
             forces, and persons kept in detention].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Navin Kapur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William O'Neill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shon Chakrabarti, MD, MPH</last_name>
    <phone>978-646-1511</phone>
    <email>schakrabarti@abiomed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Cameron</last_name>
    <phone>978.882.8434</phone>
    <email>ccameron@abiomed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Good Samaritan Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lizette Cruz</last_name>
      <email>marquez@shc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Deepak Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anthony Hospital</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Coleman</last_name>
      <email>SuzanneColeman@centura.com</email>
    </contact>
    <investigator>
      <last_name>Nima Aghili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Health Care</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorraine Marshall</last_name>
      <email>lmarshall@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Reiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health, Inc</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellstar/Kennestone Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Smalley</last_name>
      <email>lsmalley@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Justin Levisay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Edward Hospital</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joan Yanz</last_name>
      <phone>630-785-2242</phone>
    </contact>
    <investigator>
      <last_name>Mark Goodwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Iowa Heart</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Castaneda</last_name>
      <phone>617-636-7537</phone>
    </contact>
    <investigator>
      <last_name>Navin Kapur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lina Fu</last_name>
      <email>lfu2@partners.org</email>
    </contact>
    <investigator>
      <last_name>Igor F. Palacious, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spectrum</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Arakelian</last_name>
      <email>Patricia.arakelian@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Haroon Faraz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin M Stein</last_name>
      <email>rmstein3@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Vijay Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10465</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Tenzler Stein</last_name>
      <email>ruth.tenzler@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Roberty Pyo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Baga</last_name>
      <email>leslie.baga@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>Nainesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cassie Andreas</last_name>
      <email>Cassandra.Andreas@AHN.ORG</email>
    </contact>
    <investigator>
      <last_name>David Lasorda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Jones</last_name>
      <phone>864-455-2290</phone>
    </contact>
    <investigator>
      <last_name>Zachary George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Garofalo</last_name>
      <email>Stephanie.Garofalo@inova.org</email>
    </contact>
    <investigator>
      <last_name>Behnam Tehrani, MID</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anterior STEMI</keyword>
  <keyword>ST-Elevated MI</keyword>
  <keyword>Cardiac Unloading</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

